8037.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 09:10):

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong...

Stats
Dagens volum	120 000
Gjennomsnittsvolum	153 406
Markedsverdi	274.52M
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0.0100 ( 2023-05-19 )
Next Dividend	HKD0 ( N/A )
P/E	-2.85
ATR14	HKD0 (0.00%)

China Biotech Services Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

China Biotech Services Økonomi

Annual	2023
Omsetning:	HKD211.99M
Bruttogevinst:	HKD34.32M (16.19 %)
EPS:	HKD-0.0991

FY	2023
Omsetning:	HKD211.99M
Bruttogevinst:	HKD34.32M (16.19 %)
EPS:	HKD-0.0991

FY	2022
Omsetning:	HKD1.85B
Bruttogevinst:	HKD1.10B (59.46 %)
EPS:	HKD0.730

FY	2021
Omsetning:	HKD623.76M
Bruttogevinst:	HKD358.02M (57.40 %)
EPS:	HKD0.0200

Financial Reports:

No articles found.

China Biotech Services Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0100 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

China Biotech Services Dividend Information - No Dividend Player

Dividend Sustainability Score: 1.007 - low (50.00%) | Divividend Growth Potential Score: 2.94 - Decrease likely (41.30%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.395	2004-08-19
Last Dividend	HKD0.0100	2023-05-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	HKD0.405	--
Avg. Dividend % Per Year	0.00%	--
Score	0.81	--
Div. Sustainability Score	1.007
Div.Growth Potential Score	2.94
Div. Directional Score	1.971	--

Next Divdend (Est)
(2041-12-30)

HKD0 Estimate 2.53 %

Dividend Stability

0.20 Very Poor

Dividend Score

0.81

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3939.HK	Ex Dividend Junior	2023-06-07	Annually	0.00%
1776.HK	Ex Dividend Junior	2023-07-11	Annually	0.00%
0817.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
2359.HK	Ex Dividend Knight	2023-06-05	Annually	0.00%
1345.HK	Ex Dividend Junior	2023-10-04	Semi-Annually	0.00%
0390.HK	Ex Dividend Junior	2023-07-19	Annually	0.00%
6626.HK	Ex Dividend Knight	2023-09-04	Annually	0.00%
1897.HK	Ex Dividend Knight	2023-07-05	Semi-Annually	0.00%
0921.HK	Ex Dividend Junior	2023-07-10	Sporadic	0.00%
0052.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.535	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.186	1.200	-6.21	-7.45	[0 - 0.3]
returnOnEquityTTM	-0.198	1.500	-3.31	-4.97	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.638	0.800	6.81	5.45	[1 - 3]
quickRatioTTM	1.543	0.800	5.63	4.50	[0.8 - 2.5]
cashRatioTTM	1.297	1.500	3.90	5.85	[0.2 - 2]
debtRatioTTM	0.152	-1.500	7.47	-10.00	[0 - 0.6]
interestCoverageTTM	-34.51	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.200	2.00	9.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.200	2.00	9.90	10.00	[0 - 20]
debtEquityRatioTTM	0.217	-1.500	9.13	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0995	1.000	-1.675	-1.675	[0.2 - 0.8]
operatingProfitMarginTTM	-0.796	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.918	1.000	0.455	0.455	[0.2 - 2]
assetTurnoverTTM	0.348	0.800	-1.015	-0.812	[0.5 - 2]
Total Score				1.007

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.23	1.000	-0.326	0	[1 - 100]
returnOnEquityTTM	-0.198	2.50	-2.13	-4.97	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.200	2.00	9.93	10.00	[0 - 30]
dividendYielPercentageTTM	3.51	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.200	2.00	9.93	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.836	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.94

China Biotech Services

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through five segments: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, Insurance brokerage, and Others segments. It also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; money lending business; provision of tumor immune cell therapy, immune cell storage, and health management services; and provision of coordination of healthcare providers services. In addition, the company markets and sells health supplements, slimming pills, Chinese medicines, and beauty products; trades in pharmaceutical intermediates; and offers insurance brokerage services. Further, it provides property investment and logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.